keyword
MENU ▼
Read by QxMD icon Read
search

Advanced Renal cell carcinoma

keyword
https://www.readbyqxmd.com/read/28078236/cabozantinib-in-advanced-renal-cell-carcinoma-a-meteor-impact-on-clinical-practice
#1
EDITORIAL
Paolo Grassi, Elena Verzoni, Alessia Mennitto, Giuseppe Procopio
No abstract text is available yet for this article.
December 2016: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28071677/renal-cell-carcinoma-in-2016-advances-in-treatment-jostling-for-pole-position
#2
Laurence Albiges, Toni K Choueiri
No abstract text is available yet for this article.
January 10, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28067459/surgical-and-oncologic-outcomes-of-laparoscopic-radical-nephrectomy-for-non-metastatic-renal-cancer-in-long-term-dialysis-patients
#3
Kenji Omae, Tsunenori Kondo, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi, Yasunobu Hashimoto, Kazunari Tanabe
This study aimed to compare the outcomes of laparoscopic radical nephrectomy (LRN) between patients undergoing dialysis for ≤240 and >240 months. Data from all dialysis patients with non-metastatic renal cell carcinoma (RCC) treated with LRN between 2008 and 2015 in our hospital were evaluated retrospectively. Patients were divided into two groups, shorter- and longer-term dialysis patients, according to the preoperative duration of dialysis (≤240 vs. >240 months). Of 174 patients, 58 (33.3%) were on longer-term dialysis...
January 9, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28061473/immunotherapy-incorporation-in-the-evolving-paradigm-of-renal-cancer-management-and-future-prospects
#4
Kenneth G Liu, Sorab Gupta, Sanjay Goel
Significant progress has been made in the management of renal cell carcinoma (RCC) during the last few decades. In early stage, localized disease, surgical resection remains the modality of choice, with no therapeutic interventions as options for post-operative therapy other than simple observation and clinical surveillance. However, treatment options in the advanced or metastatic setting are increasing at a dizzying pace, initially with cytokine therapy, then with the increased availability of targeted therapy including novel small-molecule inhibitors of receptor tyrosine kinases and monoclonal antibodies targeting novel proteins, establishing them as the current standard of care...
December 30, 2016: Oncotarget
https://www.readbyqxmd.com/read/28055301/autophagy-orchestrates-adaptive-responses-to-targeted-therapy-in-endometrial-cancer
#5
Núria Eritja, Bo-Juen Chen, Ruth Rodríguez-Barrueco, Maria Santacana, Sònia Gatius, August Vidal, Maria Dolores Martí, Jordi Ponce, Laura Bergadà, Andree Yeramian, Mario Encinas, Joan Ribera, Jaume Reventós, Jeff Boyd, Alberto Villanueva, Xavier Matias-Guiu, Xavier Dolcet, David Llobet-Navàs
Targeted therapies in endometrial cancer (EC) using kinase inhibitors rarely result in complete tumor remission and are frequently challenged by the appearance of refractory cell clones, eventually resulting in disease relapse. Dissecting adaptive mechanisms is of vital importance to circumvent clinical drug resistance and improve the efficacy of targeted agents in EC. Sorafenib is an FDA-approved multitarget tyrosine and serine/threonine kinase inhibitor currently used to treat hepatocellular carcinoma, advanced renal carcinoma and radioactive iodine-resistant thyroid carcinoma...
January 5, 2017: Autophagy
https://www.readbyqxmd.com/read/28050490/renal-cell-carcinoma-with-unusual-skeletal-metastasis-to-tibia-and-ankle-a-case-report-and-review-of-literature
#6
Kiran Shankar, Durgesh Kumar, Kariyanakatte Veeraiah Veerendra Kumar, Chennagiri Premlata
Renal Cell Carcinoma (RCC) accounts for 5% of the epithelial malignancies worldwide with clear cell carcinoma accounting for 85% of these malignancies. One third of these patients experience synchronous metastatic disease and 20-30% of the remaining patients experience metachronous metastatic RCC. Bony metastasis accounts for 20% of metastatic RCC. They most commonly affect the axial skeleton and rarely the long bones or the small bones of the hands and feet. Bone metastases from RCC are predominantly osteolytic in nature, leading to significant patient morbidity due to the associated Skeletal Related Events (SRE)...
November 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28045610/evolving-treatment-of-oligometastatic-hormone-sensitive-prostate-cancer
#7
Jessica M Clement, Christopher J Sweeney
Oligometastatic disease was postulated by Hellman and Weichselbaum in 1995 to be a disease state that may reflect a time point in the malignant process that may be amenable to local therapies to allow for patients to achieve a durable response or possible cure despite having advanced disease. Aggressive metastasis-directed therapy has been used in malignancies such as renal cell carcinoma, non-small-cell lung cancer, and colorectal cancer with some evidence of long-term benefit in selected patients. Recently, it has been proposed that some men with oligometastatic hormone-sensitive prostate cancer may also benefit from metastasis-directed therapy...
January 3, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28040423/prognostic-significance-of-increases-in-hemoglobin-in-renal-cell-carcinoma-patients-during-treatment-with-vegf-directed-therapy
#8
Abhishek Tripathi, Susanna Jacobus, Hope Feldman, Toni K Choueiri, Lauren C Harshman
BACKGROUND: Increases in hemoglobin have been reported in renal cell carcinoma (RCC) patients treated with vascular endothelial growth factor (VEGF) pathway-targeted therapies and have been associated with increased progression-free survival (PFS). We retrospectively evaluated its significance as a predictive biomarker of clinical response in RCC. PATIENTS AND METHODS: Patients with advanced RCC treated with VEGF receptor tyrosine kinase inhibitors (TKIs) or bevacizumab as a first-line therapy were identified...
December 13, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28035577/c-met-in-chromophobe-renal-cell-carcinoma
#9
Franziska Erlmeier, Philipp Ivanyi, Arndt Hartmann, Michael Autenrieth, Max Wiedemann, Wilko Weichert, Sandra Steffens
c-Met plays a role as a prognostic marker in clear cell renal cell carcinoma. In addition, recently the tyrosine kinase inhibitor cabozantinib targeting c-Met was approved for the treatment of advanced renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known about c-Met expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of c-Met expression on chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated...
February 2017: Medical Oncology
https://www.readbyqxmd.com/read/28032079/oncology-gold-standard%C3%A2-practical-consensus-recommendations-2016-for-treatment-of-advanced-clear-cell-renal-cell-carcinoma
#10
U Batra, P M Parikh, K Prabhash, H B Tongaonkar, P Chibber, D Dabkara, C Deshmukh, N Ghadyalpatil, S Hingmire, A Joshi, S K Raghunath, S Rajappa, R Rajendranath, S K Rawal, Manisha Singh, R Singh, S P Somashekhar, R Sood
The Oncology Gold Standard (OGS) Expert Group on renal cell carcinoma (RCC) developed the consensus statement to provide community oncologists practical guidelines on the management of advanced clear cell (cc) RCC using published evidence, practical experience of experts in real life management, and results of a nationwide survey involving 144 health-care professionals. Six broad question categories containing 33 unique questions cover major situations in the routine management of RCC. This document serves as a ready guide for the standard of care to optimize outcome...
October 2016: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28031424/the-dart-study-results-from-the-dose-escalation-and-expansion-cohorts-evaluating-the-combination-of-dalantercept-plus-axitinib-in-advanced-renal-cell-carcinoma
#11
Martin H Voss, Rupal S Bhatt, Elizabeth R Plimack, Brian I Rini, Robert S Alter, J Thaddeus Beck, Dawn Wilson, Xiaosha Zhang, Musa Mutyaba, Chad Glasser, Kenneth M Attie, Matthew L Sherman, Shuchi S Pandya, Michael Atkins
PURPOSE: Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis. Concurrent targeting of ALK1 and vascular endothelial growth factor (VEGF) signaling results in augmented inhibition of tumor growth in renal cell carcinoma (RCC) xenograft models. Dalantercept is an ALK1 receptor-fusion protein that acts as a ligand trap for bone morphogenetic proteins (BMP) 9 and 10. The DART Study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept plus axitinib in patients with advanced RCC and determined the optimal dose for further testing...
December 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28030807/high-expression-of-the-long-non-coding-rna-heircc-promotes-renal-cell-carcinoma-metastasis-by-inducing-epithelial-mesenchymal-transition
#12
Jing Xiong, Ying Liu, Shengjun Luo, Li Jiang, Yang Zeng, Zhixiong Chen, Xiaobo Shi, Bufan Lv, Wei Tang
Increasing evidence indicates that long non-coding RNAs (lncRNAs) have been associated with cancer development. However, the contributions of lncRNAs to renal cell carcinoma (RCC) remain poorly characterized. Here, we identified a novel lncRNA, termed HEIRCC, which was up-regulated in RCC tissues through lncRNA microarray analysis and subsequent validation in 60 RCC clinical specimens and cell lines. The high expression of HEIRCC is associated closely with the clinical pathology features such as larger tumor size, poor differentiation, lymphatic metastasis...
December 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/28029648/genomic-differences-between-black-and-white-patients-implicate-a-distinct-immune-response-to-papillary-renal-cell-carcinoma
#13
David J Paulucci, John P Sfakianos, Anders J Skanderup, Kathleen Kan, Che-Kai Tsao, Matthew D Galsky, A Ari Hakimi, Ketan K Badani
Significant disparities in survival, incidence and possibly response to current therapies exist between black and white patients with renal cell carcinoma (RCC). Recent genomic evidence to account for these disparities has been reported for clear cell RCC. However, racial disparities at the genomic level for papillary RCC (pRCC) which is a genetically distinct and less responsive histologic subtype of RCC have not been reported. Using The Cancer Genome Atlas (TCGA) data, the present study assessed gene-level expression, somatic mutation and pathway differences between 58 black and 58 white patients with pRCC propensity matched on age, gender and pathologic T stage...
December 23, 2016: Oncotarget
https://www.readbyqxmd.com/read/28028797/glut1-mct1-4-and-cd147-overexpression-supports-the-metabolic-reprogramming-in-papillary-renal-cell-carcinoma
#14
L M C A Almeida, R Silva, B Cavadas, J Lima, L Pereira, P Soares, M Sobrinho-Simões, J M Lopes, V Máximo
Papillary Renal Cell carcinoma (pRCC) is the second most common type of RCC, accounting for about 15% of all RCCs. Surgical excision is the main treatment option. Still, 10 - 15 % of clinically localized tumours will recur and/or develop metastasis early after surgery, and no reliable prognostic biomarkers are available to identify them. It is known that pRCC cells rely on high rates of aerobic glycolysis, characterized by the up-regulation of many proteins and enzymes related with the glycolytic pathway. However, a metabolic signature enabling the identification of advanced pRCC tumours remains to be discovered...
December 28, 2016: Histology and Histopathology
https://www.readbyqxmd.com/read/28027741/transarterial-embolization-tae-as-add-on-to-percutaneous-radiofrequency-ablation-rfa-for-the-treatment-of-renal-tumors-review-of-the-literature-overview-of-state-of-the-art-embolization-materials-and-further-perspective-of-advanced-image-guided-tumor-ablation
#15
REVIEW
C M Sommer, L Pallwein-Prettner, D F Vollherbst, R Seidel, C Rieder, B A Radeleff, H U Kauczor, F Wacker, G M Richter, A Bücker, T Rodt, A Massmann, P L Pereira
Percutaneous radiofrequency ablation (RFA) for the treatment of stage I renal cell carcinoma has recently gained significant attention as the now available long-term and controlled data demonstrate that RFA can result in disease-free and cancer-specific survival comparable with partial and/or radical nephrectomy. In the non-controlled single center trials, however, the rates of treatment failure vary. Operator experience and ablation technique may explain some of the different outcomes. In the controlled trials, a major limitation is the lack of adequate randomization...
January 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28011500/a-study-of-angiogenesis-markers-in-patients-with-renal-cell-carcinoma-undergoing-therapy-with-sunitinib
#16
Clive Stubbs, Antonio D Bardoli, Mehran Afshar, Sarah Pirrie, Manuela Miscoria, Isabella Wheeley, Emilio Porfiri
BACKGROUND: Sunitinib is a tyrosine kinase inhibitor (TKI) targeting tumour angiogenesis in patients with advanced renal cell carcinoma (RCC). Currently no universally agreed model exists correlating the expression of angiogenesis markers with the success of treatment. PATIENTS AND METHODS: We retrospectively analysed archival tissue for 59 RCC patients treated with sunitinib. The expression of angiogenesis markers VEGF-A, VEGFR, PDGFββ, PDGFR, CCND1 and CA9 was assessed by immunohistochemistry (IHC) and correlated with overall survival (OS) and progression-free survival (PFS)...
January 2017: Anticancer Research
https://www.readbyqxmd.com/read/27995579/recent-advances-in-the-medical-treatment-of-recurrent-or-metastatic-renal-cell-cancer
#17
REVIEW
Rekha A Kumbla, Robert A Figlin, Edwin M Posadas
Renal cell carcinoma (RCC) historically has had limited treatment options in the metastatic setting but in the last decade, a significant arsenal of new therapies has emerged. Specifically, targeted anti-angiogenic therapies through vascular endothelial growth factor (VEGF) inhibition and immunotherapy through PD-1 inhibition have become the foundation of metastatic RCC treatment increasing not only progression-free survival but also an improved overall survival with improved toxicity profiles compared with older therapies such as IL-2 and interferon...
December 19, 2016: Drugs
https://www.readbyqxmd.com/read/27991910/establishment-and-characterization-of-bhd-f59rsvt-an-immortalized-cell-line-derived-from-a-renal-cell-carcinoma-in-a-patient-with-birt-hogg-dub%C3%A3-syndrome
#18
Mitsuko Furuya, Hisashi Hasumi, Masaya Baba, Reiko Tanaka, Yasuhiro Iribe, Takahiro Onishi, Yoji Nagashima, Yukio Nakatani, Yasuhiro Isono, Masahiro Yao
Hereditary renal cell carcinomas (RCCs) are life-threatening disorders not only for the patients but also for their relatives. Birt-Hogg-Dubé syndrome (BHD) is an autosomal dominant disorder caused by germline mutations in the folliculin gene (FLCN). The protein product, FLCN, functions as a tumor suppressor, and the affected patients have high risks of developing multiple RCCs. The carcinogenic mechanisms stemming from FLCN dysfunction have been investigated using rodent models and human RCC tissues. However, very limited information has been available about in vitro signaling of human renal cells with genetically mutant FLCN...
December 19, 2016: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/27984237/rhabdoid-and-undifferentiated-phenotype-in-renal-cell-carcinoma-analysis-of-32-cases-indicating-a-distinctive-common-pathway-of-dedifferentiation-frequently-associated-with-swi-snf-complex-deficiency
#19
Abbas Agaimy, Liang Cheng, Lars Egevad, Bernd Feyerabend, Ondřej Hes, Bastian Keck, Stefano Pizzolitto, Stefano Sioletic, Bernd Wullich, Arndt Hartmann
Undifferentiated (anaplastic) and rhabdoid cell features are increasingly recognized as adverse prognostic findings in renal cell carcinoma (RCC), but their molecular pathogenesis has not been studied sufficiently. Recent studies identified alterations in the Switch Sucrose nonfermentable (SWI/SNF) chromatin remodeling complex as molecular mechanisms underlying dedifferentiation and rhabdoid features in carcinomas of different organs. We herein have analyzed 32 undifferentiated RCCs having in common an undifferentiated (anaplastic) phenotype, prominent rhabdoid features, or both, irrespective of the presence or absence of conventional RCC component...
December 14, 2016: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27983522/different-expression-patterns-of-histone-h3k27-demethylases-in-renal-cell-carcinoma-and-bladder-cancer
#20
Zehui Hong, Hui Li, Lili Li, Weilong Wang, Ting Xu
OBJECTIVE: UTX and JMJD3 are recently identified histone H3 lysine 27 (H3K27) demethylases. Many studies have shown aberrant H3K27 trimethylation (H3K27me3) levels widely exist in multiple cancers, and that altered H3K27me3 levels are correlated with tumorigenesis and tumor progression. To investigate expression patterns of UTX and JMJD3 genes in renal cell carcinoma (RCC) and bladder cancer and the relationship between gene expression and tumor development. MATERIAL AND METHODS: Samples were collected from 35 patients with RCC and 21 patients with bladder cancer and qRT-PCR was performed...
December 9, 2016: Cancer Biomarkers: Section A of Disease Markers
keyword
keyword
65562
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"